[{"id":"e55f95f8-d9d3-4e7f-b7d3-cecaaa17625a","acronym":"CLIC-01","url":"https://clinicaltrials.gov/study/NCT03765177","created_at":"2021-01-18T18:37:56.876Z","updated_at":"2024-07-02T16:35:30.469Z","phase":"Phase 1/2","brief_title":"CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies","source_id_and_acronym":"NCT03765177 - CLIC-01","lead_sponsor":"Ottawa Hospital Research Institute","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CLIC-1901"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/16/2019","start_date":" 10/16/2019","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/31/2037","study_completion_date":" 10/31/2037","last_update_posted":"2023-11-03"}]